HCB101 + toripalimab

HCB101 + toripalimab is an investigational combination therapy comprising two agents: HCB101, a novel immunotherapy drug (precise mechanism not established in public sources), and toripalimab, a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor[1][3][6]. Toripalimab blocks the PD-1 receptor, preventing interaction with its ligands and enhancing T-cell mediated immune responses against tumor cells[2][4][6]. The combination is being evaluated in early clinical studies for the treatment of advanced solid tumors, with the primary aim of improving anti-tumor efficacy through dual or complementary immune modulation[1][3]. Toripalimab is approved for several cancers in China and the US but the combination with HCB101 is experimental.

Brand names

Tuoyi

Other names

HCB101 + toripalimab